CNS GLP-1 regulation of peripheral glucose homeostasis

Physiology and Behavior

Volumn 94, Issue 5, 2008, Pages 670-674

  Sandoval, Darleen ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

GLP 1; Glucose metabolism; Hypothalamus

Indexed keywords

AGOUTI RELATED PROTEIN; ANOREXIGENIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERMEDIN; MELANOCORTIN; MELANOCORTIN RECEPTOR; MESSENGER RNA; NEUROPEPTIDE GAMMA; POTASSIUM CHANNEL BLOCKING AGENT;

ANOREXIA; ARCUATE NUCLEUS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CORE TEMPERATURE; ENERGY EXPENDITURE; ENZYME REGULATION; FEEDBACK SYSTEM; FLUID INTAKE; FOOD INTAKE; FOREBRAIN; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN RELEASE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NERVE CONDUCTION; STOMACH EMPTYING; THALAMUS MIDLINE NUCLEUS; VAGUS NERVE STIMULATION;

EID: 45449089337     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2008.04.018     Document Type: Article

References (98)

1. McIntyre N., Holsworth D.C., and Turner D.S. New interpretation of oral glucose tolerance. Lancet 2 (1964) 20-21
2. Kreymann B., Ghatei M.A., Williams G., and Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1303
3. Jin S.L., Han V.K.M., Simmons J.G., Towle A.C., Lauder J.M., and Lund P.K. Distribution of glucagonlike peptide 1, glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271 (1988)
4. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., and Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42 (1993) 1678-1682
5. Kinzig K.P., D'Alessio D.A., Herman J.P., Sakai R.R., Vahl T.P., Figueredo H.F., et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23 (2003) 6163-6170
6. Kinzig K.P., D'Alessio D.A., and Seeley R.J. The diverse roles of CNS GLP-1 in the control of food intake and the mediation of visceral illness. J Neurosci 22 (2002) 10470-10476
7. van Dijk G., Thiele T.E., Seeley R.J., Woods S.C., and Bernstein I.L. Glucagon-like peptide-1 and satiety?. Nature 385 (1997) 214
8. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., and Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271 (1996) E808-E813
9. Kakei M., Yada T., Nakagawa A., and Nakabayashi H. Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. Auton Neurosci 102 (2002) 39-44
10. Obici S., Feng Z., Morgan K., Stein D., Karkanias G., and Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51 (2002) 271-275
11. Pocai A., Lam T.K., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434 (2005) 1026-1031
12. Pocai A., Morgan K., Buettner C., Gutierrez-Juarez R., Obici S., and Rossetti L. Central leptin acutely reverses diet-induced hepatic insulin resistance. Diabetes 54 (2005) 3182-3189
13. Lam T.K., Gutierrez-Juarez R., Pocai A., and Rossetti L. Regulation of blood glucose by hypothalamic pyruvate metabolism. Science 309 (2005) 943-947
14. Drucker D.J. Glucagon and the glucagon-like peptides. Pancreas 5 (1990) 484-488
15. Goke R., Fehmann H., and Goke B. Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. J Clin Invest 135 (1991) 135-144
16. D'Alessio D.A., Thirlby R., Laschansky E.C., Zebroski H., and Ensinck J.W. Response of GLP-1 to nutrients in humans. Digestion 54 (1993) 377-379
17. Mojsov S., Weir G.C., and Habener J. Insulinotropin: glucagon-like peptide 1 (7-37) co- encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79 (1987) 616-619
18. Williams B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide 1 (GLP-1)-(7-36) amide in type 2 diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
19. Schirra J., Nicolaus M., Roggel R., Katschinski M., Storr M., Woerle H.J., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55 (2006) 243-251
20. Prigeon R.L., Quddusi S., Paty B., and D'Alessio D.A. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285 (2003) E701-E707
21. Valverde I., Morales M., Clemente F., Lopez-Delgado M.I., Delgado E., Perea A., et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349 (1994) 313-316
22. Alcantara A.I., Morales M., Delgado E., Lopez-Delgado M.I., Clemente F., Luque M.A., et al. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 341 (1997) 1-7
23. Redondo A., Trigo M.V., Acitores A., Valverde I., and Villanueva-Penacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204 (2003) 43-50
24. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat [see comments]. J Clin Invest 95 (1995) 417-421
25. Kolligs F., Fehmann H.C., Goke R., and Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44 (1995) 16-19
26. D'Alessio D.A., Vogel R., Prigeon R., Laschansky E., Koerker D., Eng J., et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97 (1996) 133-138
27. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., Ghatei M.A., et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 (1999) 86-93
28. Han V.K.M., Hynes M.A., Jin C., Towle A.C., Lauder J.M., and P.K.L. Cellular localization of proglucagon/glucagon-like peptide 1 messenger RNAs in rat brain. J Neurosci 16 (1986) 97-107
29. Vrang N., Hansen M., Larsen P.J., and Tang-Christensen M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 1149 (2007) 118-126
30. Merchenthaler I., Lane M., and Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403 (1999) 261-280
31. van Dijk G., Thiele T.E., Donahey J.C.K., Campfield L.A., Smith F.J., Burn P., et al. Central infusion of leptin and GLP-1 (7-36) amide differentially stimulate c-Fos-like immunoreactivity in the rat brain. Am J Physiol 271 (1996) R1096-R1100
32. Thiele T.E., Seeley R.J., D'Alessio D., Eng J., Bernstein I.L., Woods S.C., et al. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801 (1998) 164-170
33. Seeley R.J., Blake K., Rushing P.A., Benoit S.C., Eng J., Woods S.C., et al. The role of CNS GLP-1-(7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20 (2000) 1616-1621
34. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., Moller M., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) R848-R856
35. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
36. Osaka T., Endo M., Yamakawa M., and Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26 (2005) 1623-1631
37. Gulpinar M.A., Bozkurt A., Coskun T., Ulusoy N.B., and Yegen B.C. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am J Physiol Gastrointest Liver Physiol 278 (2000) G924-G929
38. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol 277 (1999) R1537-R1540
39. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
40. van Dijk G., Thiele T.E., Seeley R.J., Woods S.C., and Bernstein I.L. Glucagon-like peptide-1 and satiety [letter; comment]. Nature 385 (1997) 214
41. Grill H.J., Carmody J.S., Amanda Sadacca L., Williams D.L., and Kaplan J.M. Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. Am J Physiol Regul Integr Comp Physiol 287 (2004) R1190-R1193
42. McMahon L.R., and Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 274 (1998) R23-R29
43. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
44. Chelikani P.K., Haver A.C., and Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288 (2005) R1695-R1706
45. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
46. Flint A., Raben A., Rehfeld J.F., Holst J.J., and Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 24 (2000) 288-298
47. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44 (1999) 81-86
48. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
49. Naslund E., Gutniak M., Skogar S., Rossner S., and Hellstrom P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68 (1998) 525-530
50. Schusdziarra V., Zimmermann J.P., and Schick R.R. Importance of orexigenic counter-regulation for multiple targeted feeding inhibition. Obes Res 12 (2004) 627-632
51. Furuse M., Matsumoto M., Mori R., Sugahara K., Kano K., and Hasegawa S. Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick. Brain Res 764 (1997) 289-292
52. Tritos N.A., Vicent D., Gillette J., Ludwig D.S., Flier E.S., and Maratos-Flier E. Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes 47 (1998) 1687-1692
53. Edwards C.M., Abbott C.R., Sunter D., Kim M., Dakin C.L., Murphy K.G., et al. Cocaine- and amphetamine-regulated transcript, glucagon-like peptide-1 and corticotrophin releasing factor inhibit feeding via agouti-related protein independent pathways in the rat. Brain Res 866 (2000) 128-134
54. Seeley R., Yagaloff K., Fisher S., Burn P., Thiele T., van D.G., et al. Melanocortin receptors in leptin effects. Nature 390 (1997) 349
55. D.A. Sandoval, D. Bagnol, S.C. Woods, D.A. D'Alessio, R.J. Seeley: Arcuate GLP-1 receptors regulate glucose homeostasis but not food intake. In Review, 2008.
56. Gustavson S., Sandoval D., Ertl A.C., Bao S., Raj S.R., and Davis S.N. Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab (2008)
57. Ma X., Bruning J., and Ashcroft F.M. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 27 (2007) 7125-7129
58. Liu L., Karkanias G.B., Morales J.C., Hawkins M., Barzilai N., Wang J., et al. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J Biol Chem 273 (1998) 31160-31167
59. Gutierrez-Juarez R., Obici S., and Rossetti L. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J Biol Chem 279 (2004) 49704-49715
60. Lam T.K., Pocai A., Gutierrez-Juarez R., Obici S., Bryan J., Aguilar-Bryan L., et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11 (2005) 320-327
61. Obici S., Feng Z., Morgan K., Stein D., Karkanias G., and Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51 (2002) 271-275
62. Obici S., Feng Z., Karkanias G., Baskin D.G., and Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5 (2002) 566-572
63. Larsen P.J., Tang-Christensen M., and Jessop D.S. Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat. Endocrinology 138 (1997) 4445-4455
64. Tang-Christensen M., Vrang N., and Larsen P.J. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47 (1998) 530-537
65. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115 (2005) 3554-3563
66. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277 (1999) R582-R590
67. Kastin A.J., Akerstrom V., and Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18 (2002) 7-14
68. Orskov C., Puolsen S., Moller M., and Holst J.J. Glucagon-like peptide 1 receptors in the subformical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 45 (1996) 832-835
69. Gross P.M., Wall K.M., Pang J.J., Shaver S.W., and Wainman D.S. Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius. Am J Physiol 259 (1990) R1131-R1138
70. Goke R., Larsen P.J., Mikkelsen J.D., and Skeikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin is a ligand of brain GLP-1 sites. Eur J Neurosci 7 (1995) 2294-2300
71. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
72. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23 (2003) 2939-2946
73. Smith G.P., Jerome C., Cushin B.J., Eterno R., and Simansky K.J. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213 (1981) 1036-1037
74. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
75. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., and Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of GLP-1. Am J Physiol 271 (1996) E808-E813
76. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
77. Wettergren A., Wojdemann M., Meisner S., Stadil F., and Holst J.J. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40 (1997) 597-601
78. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., and Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273 (1997) G920-G927
79. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
80. Cherrington A.D. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48 (1999) 1198-1214
81. Postic C., Shiota M., Niswender K.D., Jetton T.L., Chen Y., Moates J.M., et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274 (1999) 305-315
82. Bergman R.N., Bier J.R., and Hourigan P.M. Intraportal glucose infusion matched to oral glucose absorption: lack of evidence for "gut factor" involvement in hepatic glucose storage. Diabetes 31 (1982) 27-35
83. Dunning B.E., Moore M.C., Ikeda T., Neal D.W., Scott M.F., and Cherrington A.D. Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs. Metabolism 51 (2002) 1324-1330
84. Galassetti P., Shiota M., Zinker B.A., Wasserman D.H., and Cherrington A.D. A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake. Am J Physiol 275 (1998) E101-E111
85. Dicostanzo C.A., Dardevet D.P., Neal D.W., Lautz M., Allen E., Snead W., et al. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol Endocrinol Metab 290 (2006) E9-E16
86. Villanueva-Penacarrillo M.L., Delgado E., Trapote M.A., Alcantara A., Clemente F., Luque M.A., et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146 (1995) 183-189
87. Wheeler M.B., Lu M., Dillon J.S., Leng X.H., Chen C., and Boyd III A.E. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133 (1993) 57-62
88. Bullock B.P., Heller R.S., and Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 (1996) 2968-2978
89. Dunphy J.L., Taylor R.G., and Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141 (1998) 179-186
90. Nakagawa A., Satake H., Nakabayashi H., Nishizawa M., Furuya K., Nakano S., et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110 (2004) 36-43
91. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148 (2007) 4965-4973
92. Quddusi S., Vahl T.P., Hanson K., Prigeon R.L., and D'Alessio D.A. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26 (2003) 791-798
93. Balkan B., and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1449-R1454
94. Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
95. Dardevet D., Moore M.C., DiCostanzo C.A., Farmer B., Neal D.W., Snead W., et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 289 (2005) G806-G814
96. Johnson K.M., Edgerton D.S., Rodewald T., Scott M., Farmer B., Neal D., et al. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293 (2007) E1085-E1091
97. Dardevet D., Moore M.C., Neal D., DiCostanzo C.A., Snead W., and Cherrington A.D. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287 (2004) E75-E81
98. Ionut V., Hucking K., Liberty I.F., and Bergman R.N. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48 (2005) 967-975